Skip to content

Reassessment Strategy in the Diagnosis of Coronary Heart Disease in Elderly

Therapeutical Impact of a Reassessment Strategy in the Diagnosis of Coronary Heart Disease in Elderly

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00224575
Acronym
IRIDIA
Enrollment
260
Registered
2005-09-23
Start date
2004-11-30
Completion date
2006-11-30
Last updated
2016-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Ischemia

Keywords

Veterans

Brief summary

Despite the effectiveness of beta-blockers and antiplatelet agents for secondary prevention of coronary heart disease, this treatments are underused in the elderly because of diagnosis uncertainty and underuse of efficient treatment. in a first time, diagnosis reassessment with invasive technique if necessary. in a second time, treatment reassessment.

Detailed description

not desired

Interventions

OTHERdiagnosis reassessment

Strategy of diagnosis reassessment following a decision tree.

OTHERDiagnosis strategy and subsequent therapeutic reassessment

Performed by geriatricians, following a decision tree, based on medical history, electrocardiogram, cardiac echotomography and stress scintigraphy

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
75 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients 75 of age or older hospitalized in a geriatric service and suspect of coronary heart disease

Exclusion criteria

* acute myocardial infarction

Design outcomes

Primary

MeasureTime frame
therapeutical impact of a reassessment strategy in the diagnosis of coronary heart disease in elderlyduring hospitalization

Secondary

MeasureTime frame
part link, in the treatment modification, with diagnosis reassessment and the part link with treatment optimization, death and rehospitalization in the subsequent 6 and 12 monthsduring hospitalization

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026